Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 65, Issue 7, Pages 1327-1329Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkq157
Keywords
interferon; ribavirin; treatment; viral hepatitis; public health
Funding
- Vertex Pharmaceuticals
Ask authors/readers for more resources
Despite the Long-term morbidity associated with hepatitis C and the availability of effective treatment, fewer than a quarter of infected individuals are treated with antiviral therapy. While this is partly related to inherent limitations of currently available medications and the underlying patient population, numerous health system barriers also exist. Fewer than half of chronic hepatitis C infections are diagnosed, relatively few are referred for treatment, and misperceptions about the disease and its treatment abound amongst patients and physicians alike. This article will discuss patient and physician factors that contribute to the undertreatment of chronic hepatitis C.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available